depended on anticholinesterase medication. The effectiveness of 3,4-diaminopyridine (3,4-DAP), a preparation that enhances acetylcholine release from motor nerve terminals, has been evaluated using a series of standardised strength measures. Sixteen patients (aged seven to 47 years) were studied in an open prospective trial, and four of them in a double blind crossover trial; existing anticholinesterase medication was continued. For the group as a whole, there was a highly significant increase in muscle strength (p < 0001; n= 16). In individual paired comparisons, 13 Each individual measurement in our study was expressed as a percentage of the lower limit of normal (%LLN), that is, the value two standard deviations below the mean for controls. The mean value of these measures ("mean strength") was then calculated for each patient, excluding individual measures that were within 5% of the normal range, that is, only muscle groups that were clearly weak were included for analysis. Because the data of Wiles et al"3 were not corrected for age, the mean strength values for the children (cases 10, 11 and 15) of necessity appear unduly low.
Statistics
The mean strength for each patient pre-and post-3,4-DAP therapy were analysed for the group as a whole and also individually using the non-parametric Wilcoxon paired samples test and the Student's paired t test.
Results

Initial Response
Fourteen patients were assessed within the first seven days of starting 3,4-DAP after the optimal dose had been established. The mean muscle strength in each case is shown before and during treatment in fig 1 . All except case 16 showed an improvement in their strength scores. Patients have been ranked in this figure in order of their pre-treatment scores. The Wilcoxon signed rank test (two tailed) was applied to these data, and showed a statistically significant improvement in mean strength scores when 3,4-DAP was added (p=0-0002; n=14).
Long term response This was studied in four patients (cases 4, 8, 13, 1). Improvement was observed in the first three of these (table 3 ) assessed before and after at least a month of treatment. In two (cases 4 and 13), the initial response had also been measured (fig 1) . Case 4 was admitted to hospital for reassessment after five years of treatment. 3,4-DAP was withdrawn for 48 hours. Strength measurements were then made and repeated one hour after a single 20 mg dose of 3,4-DAP. similar results five years later when measured by a different assessor.
Comparison of strength measures
To compare the effects of 3,4-DAP treatment between individual patients, the data in all 16 patients (14 initial response, two long term response) have been normalised by expressing them as the percentage change in mean strength (fig 3) . Fourteen patients showed improvement in strength ranging from 12% to 142%. In the two patients showing no improvement, the values for % change were -6% and -7% respectively. For the group as a whole, there was a highly significant increase in muscle strength (p < 0-001, n = 16; Student's paired t test).
Individual patient analysis
Analysis of the different measures (n = [8] [9] [10] made in each of the 16 patients before and during treatment with 3,4-DAP, showed a significant improvement in 13 (table 3; 1-tailed t test). One patient (case 16) was significantly worse. parasthesia they experienced whether the preparation was active or not. Each of the four patients improved significantly on the 3,4-DAP (fig 4) , p values ranging from 0-01 to 0-002 (Wilcoxon).
Discussion
The compound 3,4-DAP when taken orally either alone or in conjuction with continued pyridostigmine therapy resulted in a statistically significant overall improvement (p <0 001) in muscle strength in a group of 16 patients with congenital myasthenia. Early improvement appeared to be sustained in those tested after periods of treatment ranging from one month to five years. Multiple performance measures including muscle force for selected muscle groups have been shown to provide a reliable index of muscle strength. 3 They are non-invasive, welltolerated by patients, and not unduly timeconsuming. Further evidence of their reliability is provided in this study, in which measures made on widely separate occasions showed considerable similarity. To avoid masking the potential benefits of the medication in the group analysis, we excluded strength measures that were either within the range of a group ofhealthy adult controls, or less than 5% below this. This might have resulted in the inclusion of some measures in the children that were in fact within the normal range for age. Each of the children tested individually, however, showed a highly significant improvement with 3,4-DAP (table 2) .
In most of the cases studied, the type of CM had not been established. However, in one of them (case 4) intercostal muscle biopsy indicated that the disorder was likely to be presynaptic,3 and the result in this individual was among the most statistically significant. By contrast, case 16, who failed to respond to edrophonium and whose end plate biopsy showed changes suggestive of the slow channel syndrome (W Squier, personal communication), strength measures were significantly decreased while he was receiving 3,4-DAP, as might be expected. These patients are also known not to respond to anticholinesterase preparations. 5 Side effects have not proved to be troublesome at the dose prescribed. This was also the case in the reported usage of 3,4-DAP in the Lambert-Eaton myasthenic syndrome.9
Most of our patients experienced perioral or distal parasthesia and some were aware of, or exhibited, mild hyperexcitability during the initial period of dose adjustment. The youngest patient in our study who received 3,4-DAP was seven years old and tolerated the drug well. A five year old girl with severe CM, who was not included in this study, also showed a striking improvement in muscle strength while taking the drug. After receiving it at home without incident for several weeks, she developed a fatal pneumonia. However, it was not thought that 3,4-DAP had contributed to this.
The results of our study suggest that 3,4-DAP, either combined with existing anticholinesterase medication or alone, may be a useful additional treatment in many cases of CM.
